Pravastatin in heterozygous familial hypercholesterolemia: Low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts

A. Gaddi, M. Arca, A. Ciarrocchi, Sergio Fazio, G. D'Alò, R. Tiozzo, G. C. Descovich, S. Calandra

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The cholesterol-lowering effect of pravastatin, a new competitive inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, was studied in 10 patients with heterozygous familial hypercholesterolemia (FH). Residual low-density lipoprotein receptor (LDL-R) activity was also evaluated in cultured skin fibroblasts prior to treatment, and showed a wide range of reduction from 30% to 70% of the normal value. Treatment with pravastatin 40 mg once daily reduced total and LDL cholesterol (LDL-C) after 6 months by 19.7% and 25.4%, respectively (P <.001). Serum apolipoprotein (apo) B levels decreased significantly by 29.1% (P <.001). No significant changes were observed in mean serum total triglycerides or high-density lipoprotein cholesterol (HDL-C) levels. A positive correlation between residual LDL-R activity and maximum percent reduction of LDL-C levels was observed (r = .676, P <.05). No clinically important side effects were recorded and the treatment was well tolerated. Thus, pravastatin effectively reduces LDL in heterozygous FH, and this effect appears to be related to LDL-R status.

Original languageEnglish (US)
Pages (from-to)1074-1078
Number of pages5
JournalMetabolism
Volume40
Issue number10
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Pravastatin
Hyperlipoproteinemia Type II
LDL Receptors
LDL Lipoproteins
LDL Cholesterol
Fibroblasts
Skin
Apolipoproteins B
Serum
HDL Cholesterol
Oxidoreductases
Reference Values
Triglycerides
Therapeutics
Cholesterol

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Pravastatin in heterozygous familial hypercholesterolemia : Low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts. / Gaddi, A.; Arca, M.; Ciarrocchi, A.; Fazio, Sergio; D'Alò, G.; Tiozzo, R.; Descovich, G. C.; Calandra, S.

In: Metabolism, Vol. 40, No. 10, 1991, p. 1074-1078.

Research output: Contribution to journalArticle

Gaddi, A. ; Arca, M. ; Ciarrocchi, A. ; Fazio, Sergio ; D'Alò, G. ; Tiozzo, R. ; Descovich, G. C. ; Calandra, S. / Pravastatin in heterozygous familial hypercholesterolemia : Low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts. In: Metabolism. 1991 ; Vol. 40, No. 10. pp. 1074-1078.
@article{97becfe4d00a47bba7887c8c11566ad1,
title = "Pravastatin in heterozygous familial hypercholesterolemia: Low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts",
abstract = "The cholesterol-lowering effect of pravastatin, a new competitive inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, was studied in 10 patients with heterozygous familial hypercholesterolemia (FH). Residual low-density lipoprotein receptor (LDL-R) activity was also evaluated in cultured skin fibroblasts prior to treatment, and showed a wide range of reduction from 30{\%} to 70{\%} of the normal value. Treatment with pravastatin 40 mg once daily reduced total and LDL cholesterol (LDL-C) after 6 months by 19.7{\%} and 25.4{\%}, respectively (P <.001). Serum apolipoprotein (apo) B levels decreased significantly by 29.1{\%} (P <.001). No significant changes were observed in mean serum total triglycerides or high-density lipoprotein cholesterol (HDL-C) levels. A positive correlation between residual LDL-R activity and maximum percent reduction of LDL-C levels was observed (r = .676, P <.05). No clinically important side effects were recorded and the treatment was well tolerated. Thus, pravastatin effectively reduces LDL in heterozygous FH, and this effect appears to be related to LDL-R status.",
author = "A. Gaddi and M. Arca and A. Ciarrocchi and Sergio Fazio and G. D'Al{\`o} and R. Tiozzo and Descovich, {G. C.} and S. Calandra",
year = "1991",
doi = "10.1016/0026-0495(91)90132-G",
language = "English (US)",
volume = "40",
pages = "1074--1078",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Pravastatin in heterozygous familial hypercholesterolemia

T2 - Low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts

AU - Gaddi, A.

AU - Arca, M.

AU - Ciarrocchi, A.

AU - Fazio, Sergio

AU - D'Alò, G.

AU - Tiozzo, R.

AU - Descovich, G. C.

AU - Calandra, S.

PY - 1991

Y1 - 1991

N2 - The cholesterol-lowering effect of pravastatin, a new competitive inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, was studied in 10 patients with heterozygous familial hypercholesterolemia (FH). Residual low-density lipoprotein receptor (LDL-R) activity was also evaluated in cultured skin fibroblasts prior to treatment, and showed a wide range of reduction from 30% to 70% of the normal value. Treatment with pravastatin 40 mg once daily reduced total and LDL cholesterol (LDL-C) after 6 months by 19.7% and 25.4%, respectively (P <.001). Serum apolipoprotein (apo) B levels decreased significantly by 29.1% (P <.001). No significant changes were observed in mean serum total triglycerides or high-density lipoprotein cholesterol (HDL-C) levels. A positive correlation between residual LDL-R activity and maximum percent reduction of LDL-C levels was observed (r = .676, P <.05). No clinically important side effects were recorded and the treatment was well tolerated. Thus, pravastatin effectively reduces LDL in heterozygous FH, and this effect appears to be related to LDL-R status.

AB - The cholesterol-lowering effect of pravastatin, a new competitive inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, was studied in 10 patients with heterozygous familial hypercholesterolemia (FH). Residual low-density lipoprotein receptor (LDL-R) activity was also evaluated in cultured skin fibroblasts prior to treatment, and showed a wide range of reduction from 30% to 70% of the normal value. Treatment with pravastatin 40 mg once daily reduced total and LDL cholesterol (LDL-C) after 6 months by 19.7% and 25.4%, respectively (P <.001). Serum apolipoprotein (apo) B levels decreased significantly by 29.1% (P <.001). No significant changes were observed in mean serum total triglycerides or high-density lipoprotein cholesterol (HDL-C) levels. A positive correlation between residual LDL-R activity and maximum percent reduction of LDL-C levels was observed (r = .676, P <.05). No clinically important side effects were recorded and the treatment was well tolerated. Thus, pravastatin effectively reduces LDL in heterozygous FH, and this effect appears to be related to LDL-R status.

UR - http://www.scopus.com/inward/record.url?scp=0026004496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026004496&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(91)90132-G

DO - 10.1016/0026-0495(91)90132-G

M3 - Article

C2 - 1658544

AN - SCOPUS:0026004496

VL - 40

SP - 1074

EP - 1078

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 10

ER -